Indication: 
Ketoanalogues/Compound α-Ketoacid Tablets are indicated for the prevention and treatment of damage caused by abnormal or insufficient protein metabolism due to chronic renal insufficiency. It is suitable for patients with daily protein intake limited to 40 grams (for adults) or less, that is, patients with a glomerular filtration rate (GFR) generally less than 25ml/min.
Strength: 0.63g/Tablet
Innovator: Fresenius Kabi Deutschland GmbH
Innovative Brand: Ketosteil
Has passed Consistency Evaluation
Qualification: Approved in China and the exported regions. Exporting to CIS/Southeast Asia.
Key selling points: 
1. Patients with chronic kidney disease require long-term treatment and management, and the Compound α-Ketoacid Tablets is affordable for long-term.